Transactions by Persons Discharging Managerial Responsibilities
Disclosure Rule DTR 3.1.4
On 30 March 2012, the following individuals, who are all persons discharging managerial responsibilities, were each granted awards under the terms of the AstraZeneca Investment Plan (AZIP) and the AstraZeneca Performance Share Plan (AZPSP) over the Company's ordinary shares, or, in the case of David Smith, Lynn Tetrault and Tony Zook, over the Company's American Depositary Shares (ADSs). One ADS equals one ordinary share. A summary of these plans can be found in the AstraZeneca Annual Report and Form 20-F Information 2011 which is available on the Company's website www.astrazeneca.com.
Name |
Shares awarded under AZIP |
Shares awarded under AZPSP |
Award price per share |
Katarina Ageborg |
3,291 |
19,747 |
2805p |
Martin Mackay |
16,764 |
100,588 |
2805p |
Jeff Pott |
8,975 |
53,850 |
2805p |
David Smith |
8,306 |
49,841 |
$44.82 |
Lynn Tetrault |
7,194 |
43,168 |
$44.82 |
Tony Zook |
16,669 |
100,014 |
$44.82 |
The AZIP award is subject to a four-year performance period (1 January 2012 to 31 December 2015) and a subsequent four-year holding period (1 January 2016 to 31 December 2019). The performance hurdle that applies to the AZIP award relates to dividends and dividend cover.
The AZPSP award is subject to a three-year performance period (1 January 2012 to 31 December 2014). The performance measures that apply to the AZPSP award relate to relative total shareholder return and cash flow.
A C N Kemp
Company Secretary
2 April 2012